Articles tagged with Cancer Genomics
Scientists at the University of Texas at Austin have developed a technique that can spot editing mistakes made by CRISPR, allowing for more precise gene therapies. The method involves rapidly testing a CRISPR molecule across a person's entire genome to foresee potential interactions.
Researchers at the University of Oxford have discovered that cancer cells manipulate a natural cell process called nonsense-mediated decay (NMD) to promote their survival. By understanding how NMD affects different types of cancer, scientists may be able to develop new treatments and therapies to control tumour growth.
A study by the University of Edinburgh reveals that dynamic DNA properties can ward off gene damage and promote genome organization. The research highlights the importance of scaffold attachment factor A in forming a protective chromatin mesh that allows for flexible and responsive cell signals.
A new technique developed by UNC School of Medicine scientists has mapped DNA damage caused by cigarette smoking at high resolution across the genome. The study provides a genome-wide map of the damage caused by benzo[α]pyrene, a chemical that accounts for about 30 percent of cancer deaths in the United States.
Raja Mazumder is developing databases BioMuta and BioXpress to standardize cancer genomics data, making it easier for researchers to integrate and compare data across various platforms. The project aims to connect cancer genomics mutation and expression data within an evolutionary context.
A recent study by Virginia Commonwealth University researchers has challenged traditional views of human papilloma virus (HPV) in HPV-related head and neck cancers. The study found that most HPV-related head and neck cancers have episomal HPV, not integrated HPV, which is associated with better treatment outcomes.
The Melanoma Research Alliance awarded Dr. Neville Sanjana a grant to use CRISPR technology to identify genetic mutations causing immunotherapy resistance in melanoma. The goal is to create a list of actionable mutations for patients enrolled in melanoma immunotherapy trials.
Researchers link cancer's high mutation rate to an ancient stress response mechanism used by single-celled organisms. The discovery sheds new light on the evolution of cancer genes and may lead to novel therapeutic approaches.
Researchers at Duke-NUS Medical School and Genome Institute of Singapore have identified altered promoters in gastric cancer that change gene expression profiles, enabling tumors to evade the immune system. The study's findings may lead to new approaches for cancer immunotherapy treatment.
Researchers analyzed DNA methylation levels in 1,900 participants to identify 58 CpGs linked to mortality. These epigenetic marks show stronger correlations with survival than previously studied genetic alterations.
Researchers analyzed 57 tissue samples from women with uterine carcinosarcoma and found that the tumors share some genetic traits but also exhibit great diversity. This diversity makes it challenging to find effective treatments for the cancer, which has a low survival rate.
Researchers have identified a new class of reader proteins linked to cancer, including leukemia. Disrupting these proteins may lead to effective combination therapies.
A new framework uses math to understand how genetic information and cell interactions give rise to tissue function, potentially aiding in understanding diseases like cancer. Researchers aim to apply this approach to real-world genome and cell biology experiments to inform future work on cancer and cell reprogramming.
Researchers at Cincinnati Children's Hospital Medical Center successfully treated patients with deadly, treatment-resistant blood cancers using gene-guided therapy. The targeted approach identified specific genes fueling the diseases and prescribed molecular drugs to put them into remission.
The APOLLO network partners with the Paulovich Laboratory to develop a panel of tests to measure key proteins in tumors, enabling targeted cancer treatments. The effort aims to improve precision-based medicine by combining genomic and proteomic approaches.
The CIViC knowledgebase is an open-access resource that allows anyone to contribute information on cancer mutations. Experts in the field curate and moderate submissions, providing a valuable resource for clinicians to identify important mutations and connect genetic errors with targeted drugs.
Researchers at Jackson Laboratory have identified a newly discovered telomere maintenance mechanism that enables cancer cells to survive and thrive. The study found that most cancer cells reactivate telomerase through TERT transcription, but the exact mechanisms behind this process remained unclear until now.
A new technique called MATQ-seq increases the accuracy of detecting gene expression in single cells to 90%, allowing scientists to study how cancerous tumors begin and potentially uncover better treatments, diagnosis, and prevention strategies.
Researchers identified novel genomic characteristics of cervical cancer, including cell signaling pathways and human papillomavirus (HPV) infection. The study also found amplification of genes involved in immune responses and potential therapeutic targets.
Researchers found 33 places in breast cancer genomes where tandem duplications were most often found, leading to further cancerous changes. These 'hotspots' may create new driver mutations, making tumours more aggressive and potentially responsive to different treatments.
A new study found that high-aneuploidy tumors have increased expression of genes involved in DNA replication and cell cycle, but decreased expression of genes characteristic of immune cells. This suggests that jumbled chromosomes in tumors may limit the effectiveness of immunotherapy treatments.
Researchers discovered cancer-driving gene mutations in uterine lavage fluid of women with and without endometrial cancer. The study's findings suggest that these pre-cancerous mutations can be detected using advanced genomic technologies, potentially leading to earlier diagnosis and improved treatment outcomes.
Three researchers were awarded the Brupbacher Cancer Research Prize for their work on epigenetics, which regulates gene activity and is linked to cancer development. The team's findings suggest that epigenetic changes can trigger abnormal gene inactivation in tumor cells.
A research team at the University of Basel has discovered a cancer type-specific 'signature' based on ribosomal protein expression. This signature may serve as a prognostic marker for cancer and point towards new therapeutic opportunities, with a strong relationship found between the signature in breast cancer and relapse-free survival.
Researchers capture elusive DNA reaction intermediates in living cells, discovering mechanisms underlying genome instability and a new role for an E. coli protein related to human cancer proteins. This breakthrough could lead to the development of new drugs that prevent cancer by neutralizing these key pieces of genetic code.
The National Cancer Institute has granted $2.5 million to Van Andel Research Institute and Cedars-Sinai to develop better diagnostic and treatment strategies for cancer. The project aims to uncover the underpinnings of cancer by analyzing epigenetic data from thousands of samples.
Researchers develop universal assay to detect cisplatin cross-linking sites in the genome. They found that mitochondrial DNA is a major target of cisplatin's action, while nuclear DNA is less affected.
Researchers from Colorado State University discovered that a cancer cell's shape may offer similar clues to predict how dangerous it is and guide treatment strategies. By analyzing cell shape using Zernike moments, the team was able to identify patterns that distinguish invasive osteosarcoma cell lines.
Scientists have long assumed chimeric RNA indicates cancer, but new research reveals these fusions can also be a normal part of human genetics. Researchers are working to develop more accurate biomarkers and therapeutic targets by understanding the complexities of normal genetic programming.
Researchers found two genomic regions changing in response to devil facial tumor disease, which has killed an estimated 80% of Tasmanian devils. The study suggests genetic resistance could help the species avoid extinction, with potential implications for cancer and immune function research.
Two key protein complexes, condensin and cohesin, play critical roles in organizing chromosomes during cell division. A recent study sheds new light on the specific functions of these proteins, which can help pinpoint the origins of genetic diseases like cancer.
A new measurement standard, developed by NIST, has been used to evaluate the performance of next-generation DNA-sequencing technologies for evaluating gene variations associated with an increased risk of breast cancer. The HER2 Standard Reference Material demonstrates its value in increasing confidence in reporting HER2 amplification f...
Researchers at Stanford Medicine developed a machine-learning approach that accurately differentiates between two types of lung cancers and predicts patient survival times better than human pathologists. The method assesses critical disease-related features, including cell size, shape, and texture, to improve patient outcomes.
Researchers found that treating human breast cancer tumors with estrogen-deprivation therapy changes the spectrum of mutations in the tumor population. This suggests using this information to improve cancer treatment. The study also discovered 'collision tumors' - separate tumors of different origin growing closely together, undiagnose...
The National Institutes of Health (NIH) has awarded $28.3 million to The Jackson Laboratory over five years to fund phase 2 of the Knockout Mouse Production and Phenotyping Project (KOMP2). This project aims to create targeted knockout mutations for every gene in the mouse genome, providing valuable clues to their function.
A Yale research team designed a system to modify multiple genes in the genome simultaneously, reducing unintended effects. The gene-editing 'toolbox' provides a user-friendly solution for studying cancer and other diseases.
A molecule believed to indicate good cancer prognosis has been shown to cause genomic instability and promote tumor growth. The study, published in Nature Cell Biology, suggests that targeting p21 could lead to new cancer treatments.
Whole-genome gene expression and methylation data offer more predictive power than commonly-used clinical information in breast cancer survival predictions. Combining these data with clinical information improves predictions, suggesting a promising genomic approach for future clinic applications.
Researchers at Jackson Laboratory aim to develop clinical adjuvants that boost vaccine effectiveness in vulnerable populations, with a focus on elderly and immunosuppressed patients. The $3.4 million grant will support the screening of new adjuvant combinations and investigation into their mechanisms of action.
Researchers have discovered a positive correlation between gene mutation 'hotspots' and better breast cancer outcomes, including lower tumor invasiveness and longer patient survival. These findings could inform prognosis and help identify patients who would best respond to immunotherapy and other treatments.
The Jackson Laboratory's Gene Expression Database (GXD) will receive $10.5 million in funding over five years to support data curation and integration, infrastructure expansion, and enhanced tools.
A recent study has identified over 200 proteins involved in cell movement and immune system function that are implicated in ovarian cancer progression. By analyzing the proteomes of 169 ovarian cancer patients, researchers have gained new insights into the biology of the disease and potential targets for treatment.
Scientists analyzed 169 ovarian cancer tumors to identify key proteins, revealing new molecular events in high-grade serous carcinoma. This proteogenomics approach combines genomic and proteomic data to improve understanding of the disease, with potential applications for precision medicine and pharmaceutical interventions.
The LawSeqSM project aims to clarify current genomic law, address gaps, and generate recommendations for a forward-looking legal foundation. This 3-year project brings together experts from academia, industry, and clinical care to create guidance on translating genomics into clinical application.
The Genomic Data Commons (GDC) brings together genomic datasets and analyzes the data using a common set of methods, democratizing the analysis of large cancer genomic datasets. This platform enables researchers to access and share high-quality data, tools, and support to accelerate studies of cancer biology and personalized treatments.
A new research paper by GMU and Inova Health System highlights the importance of proteins in personalized medicine, particularly in cancer treatment. The study suggests that targeting proteins can lead to more effective treatments for patients with metastatic breast cancer.
A new study published in Nature Medicine highlights the potential of big data to unlock the secrets inside cancer cells and enable more effective personalised treatments. The study proposes a blueprint for sharing patient data to improve patient outcomes.
Researchers created cell lines with targeted chromosomal deletions to study the role of specific chromosomal losses in cancer development. The findings suggest that chromosomal engineering is a more effective approach than studying individual genes or micro-RNAs.
Scientists have found conclusive evidence that a specific jumping gene plays a key role in generating some colon tumors. The study reveals how this gene can trigger cancer by causing mutations in other genes that suppress cancer. Researchers discovered 27 L1 insertions in the tumor, which were not found in surrounding healthy tissue.
Researchers identified three subtypes of ACC with distinct clinical outcomes and molecular alterations. The study also found novel ACC driver genes and suggests that inhibiting whole genome doubling could slow tumor growth. These findings may inform therapeutic decisions and lead to significant advances in patient outcomes.
A study published in Cancer Cell identified a third class of ACC, associated genes, and potential treatment targets. The research aims to provide better treatments for this rare cancer with significant side effects from current therapies.
Researchers found more than half of the genes studied showed sex-biased signatures in certain cancer types, revealing two sex-effect groups associated with distinct incidence and mortality profiles. These findings lay a critical foundation for precision cancer medicine that is sex-specific.
Researchers from 39 institutions worldwide analyzed 91 samples of adrenocortical carcinoma, uncovering double the number of genetic drivers known to fuel adrenal cancer. The study also identified three distinct subtypes of adrenal cancer linked to different outcomes, suggesting a way to use molecular biomarkers for targeted therapy.
Researchers have identified five new gene regions associated with an increased risk of developing endometrial cancer, bringing the total number of known risk regions to nine. This discovery doubles the number of genetic risk factors known for the disease, which affects one in four women worldwide.
Researchers developed a new computer algorithm called REVEALER to identify groups of genetic variations associated with cancer cell activation and treatment responses. Using large tumor genomics database The Cancer Genome Atlas, REVEALER revealed new gene mutations linked to cancer development and treatment resistance.
Scientists have identified 182 genome instability suppressing (GIS) genes in yeast and over 400 previously unknown cooperating GIS genes. These findings suggest a complex genetic network maintaining genome integrity and highlight potential therapeutic targets for cancer treatment.
Researchers discover circular RNAs involved in tumor growth and progression, suggesting a new path to cancer treatments. The study provides insights into the role of non-coding RNA in human biology and disease.
Researchers found that cancer cells have a resilient ability to repair nuclear envelope rupture during cell migration, but this process compromises genomic integrity. The study highlights a potential weakness in metastatic cancer cells and an opportunity for developing novel anti-metastatic drugs.
Researchers identified a new subtype of muscle-invasive bladder cancer that resembles some forms of breast cancer, characterized by low levels of the tight junction protein claudin. These claudin-low tumors express high levels of immune-related genes but also show a strong signature of immunosuppression.
Researchers have identified nine distinct subtypes of kidney cancer, each with unique molecular pathways and patient survival outcomes. These findings hold promise for personalized medicine by identifying specific targets for therapies.